CFDA approved our IND application of Pirotinib Hydrochloride (KBP-5209)
2015-08-07 16:41:07 Author:admin

     CFDA approved our IND application of Pirotinib Hydrochloride (KBP-5209) today and more importantly granted us a full permission of clinical trials I-III! This unusual approval suggests not only a big leap in progress of our government regulatory agency, but also an ever-growing capabilities of our R&D.The project will be moved forward in US and China simotaniously after FIH is realized expectedly in coming October. This model of a China-centric internaltional multi-center clinical trial is a new innovation and will expect to impact pharma industry significantly. 

Email | Terms of Use | Contact us

2014版權?軒竹醫藥科技有限公司保留所有權利 魯ICP備09030169號

圣盛湖北公安晃晃麻将 国外彩票澳洲幸运8 澳洲幸运8是真的吗 玩呗麻将牌怎么下载 泰和新材股票 免费四川麻将血战到 选涨停股票公式 2020年第9期开奖日期 上海11选5预测中奖方式 2019平特肖规律网址 星悦云南麻将怎么下载安装